(Q37925018)

25 August 2017

1 reference

title

Targeting inflammation in cardiovascular diseases. still a neglected field? (English)

1 reference

25 August 2017

0 references

cardiovascular disease

1 reference

based on heuristic

inferred from title

author name string

Carmen Gómez-Guerrero

series ordinal

1

1 reference

25 August 2017

Beñat Mallavia

series ordinal

2

1 reference

25 August 2017

Jesus Egido

series ordinal

3

1 reference

25 August 2017

publication date

1 April 2011

1 reference

Cardiovascular Therapeutics

25 August 2017

published in

1 reference

25 August 2017

volume

30

1 reference

25 August 2017

issue

4

1 reference

25 August 2017

page(s)

e189-97

1 reference

Atherosclerosis--an immune disease: The Anitschkov Lecture 2007.

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Immune and inflammatory mechanisms of atherosclerosis (*)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Immune-mediated mechanisms in atherosclerosis: prevention and treatment of clinical manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Innate immunity, Toll-like receptors, and atherosclerosis: mouse models and methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

The monocyte/macrophage as a therapeutic target in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Cytokines in atherosclerosis: pathogenic and regulatory pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Impact of innate inflammation in population studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Insights into the role of infection in atherogenesis and in plaque rupture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Autoimmunity in atherosclerosis: a protective response losing control?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Oxidation-specific epitopes are important targets of innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

The immune response in atherosclerosis: a double-edged sword

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Atherogenesis and the humoral immune response to modified lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Immunocytochemical detection of Fcgamma receptors in human atherosclerotic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Fcgamma receptor deficiency confers protection against atherosclerosis in apolipoprotein E knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Deletion of the Fc receptors gamma chain preserves endothelial function affected by hypercholesterolaemia in mice fed on a high-fat diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Immunoglobulin treatment suppresses atherosclerosis in apolipoprotein E-deficient mice via the Fc portion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Intravenous immunoglobulin and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Intravenous immunoglobulin - indications and mechanisms in cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Low- but not high-dose FK506 treatment confers atheroprotection due to alternative macrophage activation and unaffected cholesterol levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Cardiovascular risk and thiazolidinediones--what do meta-analyses really tell us?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Innate immunity and toll-like receptor antagonists: a potential role in the treatment of cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

The role of complement activation in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

C1-esterase inhibitor protects against neointima formation after arterial injury in atherosclerosis-prone mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

C5a receptor targeting in neointima formation after arterial injury in atherosclerosis-prone mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Complement activity and pharmacological inhibition in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Pharmacokinetics of C1-inhibitor protein in patients with acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Regulatory T-cell immunity and its relevance to atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

The Th17/Treg imbalance in patients with acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Oral anti-CD3 antibody treatment induces regulatory T cells and inhibits the development of atherosclerosis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Anti-CD3 mAbs for treatment of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Role for TNF in atherosclerosis? Lessons from autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Atherogenic effect of interleukin-2 and antiatherogenic effect of interleukin-2 antibody in apo-E-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Interleukin 18 binding protein (IL18-BP) inhibits neointimal hyperplasia after balloon injury in an atherosclerotic rabbit model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Targeting the development and effector functions of TH17 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

IL-33 reduces the development of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Chemokines in atherosclerosis: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Anti-chemokine small molecule drugs: a promising future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Requirement for p38 mitogen-activated protein kinase activity in neointima formation after vascular injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

BMS-582949: crystalline form of a p38alpha inhibitor? WO2008079857.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Therapeutic promise of JNK ATP-noncompetitive inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

PI3Kgamma inhibition: towards an 'aspirin of the 21st century'?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Genetic and pharmacological targeting of phosphoinositide 3-kinase-gamma reduces atherosclerosis and favors plaque stability by modulating inflammatory processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

JANUS under stress--role of JAK/STAT signaling pathway in vascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Role of the Jak/STAT pathway in the regulation of interleukin-8 transcription by oxidized phospholipids in vitro and in atherosclerosis in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Signal transducer and activator of transcription-1 is critical for apoptosis in macrophages subjected to endoplasmic reticulum stress in vitro and in advanced atherosclerotic lesions in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

New approaches to the treatment of inflammatory disease : focus on small-molecule inhibitors of signal transduction pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Fludarabine prevents smooth muscle proliferation in vitro and neointimal hyperplasia in vivo through specific inhibition of STAT-1 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

STAT1 as a new molecular target of anti-inflammatory treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Suppressors of cytokine signaling regulate angiotensin II-activated Janus kinase-signal transducers and activators of transcription pathway in renal cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Suppressors of cytokine signaling abrogate diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Treatment of mice with the suppressor of cytokine signaling-1 mimetic peptide, tyrosine kinase inhibitor peptide, prevents development of the acute form of experimental allergic encephalomyelitis and induces stable remission in the chronic relapsing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Roles of NF-kappaB in health and disease: mechanisms and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Nuclear factor kappaB signaling in atherogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Parthenolide modulates the NF-kappaB-mediated inflammatory responses in experimental atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Endothelial cell-specific NF-kappaB inhibition protects mice from atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Inhibitors of NF-kappaB signaling: 785 and counting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Pomegranate phenolics from the peels, arils, and flowers are antiatherogenic: studies in vivo in atherosclerotic apolipoprotein e-deficient (E 0) mice and in vitro in cultured macrophages and lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Antiinflammatory and antiatherogenic effects of the NF-kappaB inhibitor acetyl-11-keto-beta-boswellic acid in LPS-challenged ApoE-/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Inhibition of NF-{kappa}B improves left ventricular remodeling and cardiac dysfunction after myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Site-specific antiatherogenic effect of the antioxidant ebselen in the diabetic apolipoprotein E-deficient mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Proteasome inhibitor bortezomib promotes a rupture-prone plaque phenotype in ApoE-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Use of cell permeable NBD peptides for suppression of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

PPARγ Activation Primes Human Monocytes into Alternative M2 Macrophages with Anti-inflammatory Properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

Anti-inflammatory and anti-atherogenic effects of cathechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00274.X

10.1111/J.1755-5922.2011.00274.X

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference